SEC Form 3 · accession 0000899243-18-008945
Myovant Sciences Ltd. · MYOV
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Period of report
Mar 19, 2018
Accepted (ET)
Mar 29, 2018 · 8:50 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001679082
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2 | holding | — | — | — | 7,420,625 | D |
Table II — derivative securities
No Table II lines on this filing.
Explanation of responses
- F1On March 19, 2018, Takeda Pharmaceuticals International AG ("TPIZ") sold 7,420,625 shares of common stock of Myovant Sciences Ltd. to Millennium Pharmaceuticals, Inc. ("Millennium"). As of the date of this filing: Millennium is owned by Takeda Pharmaceuticals U.S.A., Inc. ("TPUSA"); 41.05% of the outstanding common stock of TPUSA is owned by TPIZ and 58.95% of the outstanding common stock of TPUSA is owned by Takeda Pharmaceuticals Company Limited ("TPC"); 86.831% of the outstanding shares of TPIZ are owned by Takeda Pharma A/S (Denmark) ("TPAS") and 13.1680% of the outstanding shares of TPIZ are owned by Takeda Europe Holdings BV (Netherlands) ("TEHBV"); TPAS is owned by Takeda A/S (Denmark) ("TAS"); 76.09% of the outstanding shares of TAS are owned by TPC and 23.91% of the outstanding shares of TAS are owned by TEHBV.
- F2(Continued from footnote 1) TEHBV is wholly-owned by TPC. TPIZ, TPC, TPAS, TEHBV and TAS previously reported this transaction on a Form 4 filed March 21, 2018. Each of the Reporting Persons (other than Millennium) disclaims beneficial ownership of the shares reported herein except to the extent of its pecuniary interest therein.
Remarks
Exhibit List: Exhibit 24.1 Power of Attorney for Takeda Pharmaceuticals U.S.A., Inc.; Exhibit 24.2 Power of Attorney for Millennium Pharmaceuticals, Inc.